The FDA decision on Eton Pharmaceuticals Inc.’s (ETON) Topiramate Oral Solution is set for August 6.Topiramate Oral Solution is proposed for three indications – as a monotherapy treatment of partial-onset or primary general tonic-clonic seizures in patients 2 years age and older; adjunctive therapy for treatment of partial-onset seizures, including seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older; and as preventative treatment of migraine in patients 12 years of age and older.Topiramate sold under the brand names Topamax, Qudexy XR Sprinkle, and Trokendi XR, among others is available in film-coated tablets and a hard capsule, and has been available since 1996. The first generic version of Topiramate, developed by Mylan Pharma, was launched in September 2006.ETON closed Monday’s (Jul.26, 2021) trading at $5.65, up 1.07%.